Tiziana Life Sciences Ltd (NQ: TLSA )
0.8729 +0.0229 (+2.69%) Streaming Delayed Price Updated: 2:59 PM EDT, Jun 1, 2023 Add to My Watchlist
Headline News about Tiziana Life Sciences Ltd
Tiziana Life Sciences To Submit Alzheimer's IND In Q2 2023, Seeks $3 Million From An Alzheimer's Foundation To Support Phase 2a Trial
April 21, 2023
Tiziana Life Sciences Ltd. (NASDAQ: TLSA) announced its plan to submit an IND for intranasal foralumab in patients with mild to moderate Alzheimer’s Disease in Q2 2023.
Tiziana Life Sciences Has Only Fully Human Anti-CD3 mAB In Clinical Studies, Could Be Poised To Improve Care For Patients With Severe Multiple Sclerosis
April 19, 2023
Tiziana Life Sciences (NASDAQ: TLSA), a London-based biotechnology company, is developing a first-in-class drug, Foralumab. Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) at the...
EXCLUSIVE: Tiziana Life Sciences Plans To Develop Multiple Sclerosis Hopeful For Long COVID Patients
April 13, 2023
Tiziana Life Sciences Ltd (NASDAQ: TLSA) plans to investigate intranasal foralumab for Long COVID. What Happened: The work is supported by foralumab's well-established role in de-activating microglia...
Treatments For Non-Active Secondary Progressive Multiple Sclerosis Remain Scarce – Tiziana Life Sciences' (NASDAQ: TLSA) First-In-Class Foralumab Is Showing Promise
April 12, 2023
Research is being done into whether there might be treatments that tackle Multiple Sclerosis (MS) through immunosuppression and a reduction of patient neuroinflammation. Anti-CD3 monoclonal antibodies...
Tiziana Receives Sign-Off From The FDA To Proceed With Phase 2 Clinical Trial In Patients With Non-Active Secondary Progressive Multiple Sclerosis (SPMS)
March 29, 2023
Tiziana Life Sciences Ltd. (NASDAQ: TLSA) announced it has received feedback based on the U.S. Food and Drug Administration (FDA) Type C meeting minutes related to the Phase 2 clinical trial of...
Why Spero Therapeutics Is Trading Higher By Over 105%; Here Are 21 Stocks Moving Premarket
September 22, 2022
Gainers Spero Therapeutics, Inc. (NASDAQ: SPRO) rose 105.6% to $1.69 in pre-market trading. GSK and Spero Therapeutics announced exclusive license agreement for late-stage antibiotic asset, Tebipenem...
This Healthcare Stock is Surging By Over 21%: Here's 24 Biggest Movers In Tuesday's Pre-Market
July 12, 2022
Gainers Versus Systems Inc. (NASDAQ: VS) rose 66% to $0.7802 in pre-market trading. Versus Systems, last month, received NASDAQ notification regarding minimum bid price deficiency.
Tiziana Life Sciences (NASDAQ: TLSA) reported clinical results from the second patient with Secondary Progressive Multiple Sclerosis (SPMS) in the ongoing study as part of an expanded access program.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following